Last reviewed · How we verify
NCT03657251
MMRF CureCloud Research Initiative
trial testing liquid biopsy in Multiple Myeloma in 1,105 participants. Terminated before completion.
29 December 2023
Quick facts
| Lead sponsor | Multiple Myeloma Research Foundation |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 1,105 |
| Start date | 14 July 2020 |
| Primary completion | 29 December 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 4 locations across United States |
Drugs / interventions tested
- liquid biopsy — full drug profile →
Conditions studied
- Multiple Myeloma — all drugs for Multiple Myeloma →
Sponsor
Multiple Myeloma Research Foundation
Who can join
18 and older, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The MMRF CureCloud Research Initiative, a Direct-to-Patient Research effort aimed at enrolling 5,000 individuals from whom comprehensive molecular and immune analyses will be generated from blood specimens and the resulting data aggregated with the correlating clinical information. Blood will be collected from all participants after electronic online consenting via a mailed blood kit designed for a mobile phlebotomy appointment. Through the consenting process, participants will also be authorizing collection of their electronic medical records information.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Liquid biopsies for multiple myeloma in a time of precision medicine.
Ferreira B, Caetano J, Barahona F, Lopes R, et al · · 2020 · cited 24× · PMID 32246161 · DOI 10.1007/s00109-020-01897-9 -
Attenuated response to SARS-CoV-2 vaccine in patients with asymptomatic precursor stages of multiple myeloma and Waldenstrom macroglobulinemia.
Konishi Y, Sklavenitis-Pistofidis R, Yue H, Ferrari F, et al · · 2022 · cited 14× · PMID 34895486 · DOI 10.1016/j.ccell.2021.12.003 -
Financial Toxicity and Satisfaction With Cancer Treatment Among Patients With Multiple Myeloma: An Analysis of the MMRF's CureCloud Initiative.
Fiala MA, Lepisto E, Amadi-Mgbenka C, Schulman J, et al · · 2026 · cited 1× · PMID 41184167 · DOI 10.1016/j.clml.2025.10.007
Verify or expand the search:
- PubMed search for NCT03657251
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of liquid biopsy
Trials testing the same drug.
- NCT06102889 — GUIDING MULTI-MODAL THERAPIES AGAINST MINIMAL RESIDUAL DISEASE BY LIQUID BIOPSIES · enrolling by invitation
- NCT04232891 — Early Detection of Relapses in Stage IV Colorectal Cancer Patients · unknown
- NCT05874115 — Development of a Biomarker to Predict the Efficacy of Anti-angiogenic Therapy in Ovarian Cancer · unknown
Other recruiting trials for Multiple Myeloma
Currently open trials in the same condition.
- NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
- NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
- NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
- NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
- NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03657251 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Multiple Myeloma Research Foundation
- Last refreshed: 5 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03657251.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing